U
ACOR

UBS’s Acorda Therapeutics ACOR Stock Holding History

UBS’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$3.89M Buy
956
+449
+89% +$1.68M ﹤0.01% 2277
2014
Q2 		$2.05M Buy
507
+77
+18% +$314K ﹤0.01% 2854
2014
Q1 		$1.96M Sell
430
-49
-10% -$198K ﹤0.01% 2806
2013
Q4 		$1.68M Buy
479
+241
+101% +$940K ﹤0.01% 2981
2013
Q3 		$975K Buy
238
+56
+31% +$241K ﹤0.01% 3366
2013
Q2 		$719K Buy
+182
New +$749K ﹤0.01% 3698

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

UBS's ACOR Position: Q3 2014 in Review

UBS increased its Acorda Therapeutics (ACOR) stake by 89% in Q3 2014, buying an estimated $1.68M and bringing the position to 956 shares worth $3.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

UBS first reported a position in ACOR in Q2 2013 and has held it in 6 quarters since. 174 funds tracked by Wall St. Rank hold ACOR as of Q3 2014.

  • UBS held 956 shares of Acorda Therapeutics worth $3.89M as of Q3 2014.
  • UBS bought 449 Acorda Therapeutics shares in Q3 2014, an estimated $1.68M.
  • Acorda Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2277 holding.
  • UBS first reported a position in Acorda Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • 174 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.